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Abstract  
Autoimmune neurologic syndromes can be paraneoplastic (associated with malignancies and/or 
onconeural antibodies), or non-paraneoplastic. Their clinical presentation is often similar. As 
prognosis is related to malignancy treatment, better biomarkers are needed to identify patients with 
malignancy. We investigated cerebrospinal fluid (CSF) markers of neuronal (neurofilament light 
chain, NFL and total tau protein, T-tau) and glial (glial fibrillary acidic protein) damage. CSF-NFL 
and T-tau were increased in both paraneoplastic and non-paraneoplastic autoimmune syndromes. 
Patients with manifest malignancies were older, had less epilepsy, more focal central and peripheral 
neurological signs and symptoms, and worse long-term outcome, than those without malignancy. 
CSF-NFL-levels predicted long-term outcome but were not diagnostic for malignancy, after age 
adjustment. 
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Introduction 
Autoimmune encephalitis is a group of autoimmune brain disorders often but not always associated 
with more or less well-characterized antibodies directed against neuronal cell membrane or 
intracellular antigens, and sometimes related to underlying malignancies. The field has expanded 
tremendously during the last years and future research will probably reveal even more antibodies 
related to these disorders. The clinical presentation is variable and can be dramatic with a 
combination of symptoms such as epileptic seizures which, when sustained, may cause status 
epilepticus, psychiatric, cognitive, behavioral and movement abnormalities (for excellent reviews, 
see (1-5). Many patients initially need intensive care treatment, some develop persistent functional 
disabilities, a significant proportion recovers remarkably well, but a few may even die. The 
treatment for these disorders is symptomatic, directed at the prevailing symptoms, such as psychosis 
or epilepsy, and causal, directed at the underlying neuroimmunological abnormality and tumor 
removal, when present (6). In those patients who do not fully recover, it may be exceedingly 
difficult to determine the cause of treatment failure: still active disease due to insufficiently treated 
immunological processes, or remission with neurological sequels? The distinction has profound 
implications for the continuing treatment, with focus on either more aggressive immunosuppression 
with its serious potential side effects, or just intensified symptomatic treatment. There are no 
biomarkers for making this distinction straightforward. Antibody titers, when specific antibodies 
have been identified, CSF immunopathy findings, when present, and MRI abnormalities, when 
visible, offer some guidance, but are not entirely reliable for determining disease activity. For 
example, in anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, although the antibody titers 
may decrease over time, they can decrease regardless of outcome, and might still be positive after 
recovery (7). MRI findings, if present, can be difficult to interpret, as they may be permanent 
sequels after remission and not a sign of still active disease (8, 9). There is still a need for better, 
more reliable biomarkers in autoimmune encephalitides.  
 
Cerebrospinal fluid (CSF) neuronal damage and glial cell markers, such as neurofilament light 
chain (NFL), total tau protein (T-tau) and glial fibrillary acidic protein (GFAP), are constituent parts 
of neurons and glial cells. They are increased non-specifically in patients with both acute and 
chronic disorders causing neuronal damage aor death, and disintegration of astroglial cells (for 
reviews, see (19, 20, 16). Considering the pathophysiology and the presenting symptoms, it may be 
suspected that the disease processes in autoimmune encephalitis may damage the brain, thus making 
the study of CSF markers of neuronal damage and glial cells relevant even in this disorder. To the 
best of our knowledge, this has not been done yet. 
 
The objective of this study is to investigate levels of CSF neuronal damage and glial cell markers in 
patients with autoimmune encephalitis and relate them to the presence of CSF immunopathy, 
antibodies to neuronal cell membrane or intracellular antigens, MRI findings, and outcomes. 
Methods 
Analysis of biographical, clinical and CSF data extracted retrospectively from patients' files.  
 
Ethics: 
Studies were approved by the regional ethics committee at the University of Gothenburg. 
 
Patients:  
Patients were identified searching in the Sahlgrenska University Hospital Electronic Database 
(Melior) using the following identifiers: all in-patients treated at the Department of Neurology or at 
the Neurointensive Care Unit, Sahlgrenska University Hospital, between January 1, 2000 and May 
20, 2014. All patients treated at this department are adults (age ≥ 18 years). Patients treated by the 
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Neurointensive Care Unit had to be there temporarily due to the seriousness of their medical 
condition. The search words used to scan patient files were: autoimmune encephalitis and variants 
of autoimmune encephalitis, such as limbic encephalitis, NMDA encephalitis. These words could 
be coded as diagnoses or just appear in the final discharge records as words, confirming, denying or 
just discussing these diagnoses. Manual verification of all search results was performed for 
identifying true patients with these diagnoses. Thereafter, data for these patients were extracted 
retrospectively from patients' files.  
The diagnostic criteria for autoimmune/limbic encephalitis were the following: 1) Clinical 
symptoms from at least one of five core clinical domains (epileptic seizures, psychiatry and 
behaviour, cognition, disorders of consciousness, movement disorders); 2) At least one of 
following: a) Pathological findings on MRI brain performed according to a specified protocol for 
autoimmune encephalitis (for visualizing unilateral or bilateral T2/FLAIR hyperintensities in the 
hippocampus/medial temporal areas in addition to standard methods); b) CSF immunopathy 
(pleocytosis, presence of oligoclonal bands, increased immunoglobulin G or increased IgG index); 
c) Presence of antibodies typical for autoimmune encephalitis (neuronal surface antibodies, 
onconeuronal antibodies, glutamic acid decarboxylase (GAD) and thyroid peroxidase (TPO) 
antibodies). 3) Presence of tumor within 2 years from diagnosis; 4) Exclusion of other diagnoses 
with a similar clinical presentation.  
 
Diagnostic work up: 
The diagnosis was based on a combination of relevant symptoms and investigational findings and 
followed the recommendation of Zuliani et al., 2012 (3). Symptoms encompassed significant 
abnormalities from the above mentioned clinical domains. Status epilepticus was defined as 
ongoing motor or psycho-motor seizures, loss of consciousness, confusion or bizarre behavior and 
electro-encephalography (EEG) showing status epilepticus, repeated seizures without recovery of 
consciousness in between, or EEG showing status epilepticus on a patient sedated for treating 
epilepsy. In addition to routine investigations with respect to infections, metabolic disruptions, 
systemic rheumatological disorders, and other conditions known to mimic autoimmune brain 
disorders, patients were systematically investigated specifically for autoimmune encephalitis. These 
investigations included brain MRI with relevant sequences, CSF analysis in regard to 
immunopathy, blood and CSF analysis in regard to relevant antibodies (for details, see diagnostic 
criteria). At least one investigational finding had to be abnormal and congruent with a diagnosis of 
autoimmune encephalitis for this diagnosis to be made.  If an alternative diagnosis could be 
considered more likely, a diagnosis of autoimmune encephalitis was not made.  A malignancy work 
up was done in all patients, including computer tomography (CT) of abdomen and chest, ultrasound 
of testes in men, gynecological evaluation and mammography in women, and whole body FDG-
PET-CT. All patients performed EEG at least once. 
 
Cerebrospinal fluid analysis: 
CSF was collected from all patients through lumbar puncture (LP) performed in the supine position. 
The CSF was always collected as part of the medical management, as deemed necessary on clinical 
grounds.  For a majority of patients LPs were performed at the time for hospitalization which 
coincided most often with the time for disease onset (LP1), at 3±1 months (LP2) and at 12±3 
months (LP3). According to the clinical situation and the wishes of the patient, the number of LPs 
could vary. Generally, the more serious the disease course was, the more LPs were performed. In 
some cases, with the patient’s written informed consent, extra CSF was sent to a biobank and frozen 
to – 80° C for later use in both the clinical management of the patient, if needed, and for research 
purposes.  
 
All analyses were performed as part of clinical routine testing by board-certified laboratory 
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technicians. The procedures used were accredited by the Swedish Board for Accreditation and 
Conformity Assessment. All samples were coded and the analyst was unaware of any patient data. 
The following routine CSF analyses were performed on all patients: cell counts, albumin and 
immunoglobulin G and M quantification, electrophoresis of CSF and serum, cytology. Neuronal 
damage and glial cell markers (NFL, GFAP, T-tau protein) were analyzed in all patients. 
 
During the study period three different methods were used for measurement of NFL concentration 
in CSF. The first was an in house ELISA with a limit of detection of 250 ng/L (ref: Rosengren LE, 
Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and 
other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Journal of 
neurochemistry 1996;67:2013-2018), which was later improved to 125 ng/L (Zetterberg H, Hietala 
MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. Archives of neurology 
2006;63:1277-1280). The third method was a novel ELISA, developed in collaboration with Uman 
Diagnostics (NF-light ELISA kit, UmanDiagnostics AB, Umeå, Sweden), with a limit of detection 
of 50 ng/L. The third method produces highly correlated results, although with higher 
concentrations. To correct for this bias the ratio of means between this method and its two 
predecessors was used for normalization (NFL old/NFL new = 0.32; for further details, see 
Skillbäck T, Farahmand B, Bartlett JW, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, 
Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H. 
Neurology. 2014 Nov 18;83(21):1945-53). The ELISA GFAP in the CSF were performed as 
previously described (11). The detection limit of the assay for GFAP was 32 ng/L. The upper limits 
of the reference range for neuronal damage markers changed June 1 2010. Until that date, they were 
for CSF NFL 250, 312 and 795 ng/L for the age groups <60, 60–69, and >70 years, respectively, for 
CSF GFAP 1250 ng/L and for CSF T-tau 400 ng/L. Beginning with June 1 2010 they were for CSF 
NFL 380, 560, 890, and 1850 ng/L for the age groups <30, 30-40, 40-60 and >60 years, 
respectively; for GFAP they were <175, <750 and <1250 ng/L for ages <20, 20-60 and ≥ 60 years; 
and for CSF T-tau they were <300 ng/L for age 18-45 years and < 400 ng/L for ages > 45 years. 
CSF total tau (T-tau) concentration was determined using a sandwich ELISA (Innotest hTAU-Ag, 
Fujirebio, Ghent, Belgium) specifically constructed to measure all tau isoforms irrespectively of 
phosphorylation status, as previously described (12). The detection limit of the T-tau ELISA was 75 
ng/L. Over the study period, the NFL and GFAP assays have had a mean inter-assay coefficient of 
variation (CV) of 15.5% and the T-tau inter-assay CV has been below 10%.  
 
Neuronal surface and paramalignant antibodies analysis:  
Blood and CSF analyses were performed in regard to the following neuronal surface, paramalignant 
(onconeuronal) and other antibodies: NMDA receptor, G-aminobutyric acid B (GABAB) receptor, 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 1 and 2 receptors, Leucine-rich 
glioma inactivated protein (LGI) 1, contactin-associated protein-like (CASPR) 2, Hu, Yo, Ri, 
Ma2/Ta, CV2/CRMP5, amphiphysin, GAD, TPO. Only a part of these investigations were available 
before 2008. 
 
Treatment: 
Patients were optimally treated for their symptoms (such as epileptic seizures, psychiatric and 
behavioral abnormalities, disturbances in homeostasis). All identified malignancies were fully 
treated. Immunosuppressive treatment was given to all patients as deemed necessary according to 
the clinical situation. All standard immunosuppressants were available, as needed, including 
corticosteroids, intravenous immunoglobulins, plasmapheresis, cyclophosphamide, rituximab, 
azatioprin, mycophenolat-mofetil. As this paper does not focus on treatment aspects, no detailed 
information regarding treatments is presented. 
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Outcome: 
Outcomes at onset, 3±1 and at 12±3 months (LP3) were evaluated retrospectively using the 
modified Rankin Scale (mRS) (13, 14). 
 
Statistical analysis:   
Nonparametric tests were used as CSF data was not normally distributed. To compare the levels of 
the different brain damage markers at the time for LP1, 2 and 3, Friedman’s two way analysis of 
variance for related samples was used. Associations were calculated with Spearman’s rank 
correlation and with partial correlations with age adjustment. Due to the low numbers of patients, 
part of the data is presented descriptively. 
Results 
Biographical and clinical data 
Details are presented in Tables 1 and 2. Twenty five patients, 17 females and 8 males, with a 
median age of 42 years (18-75 years) were treated for some form of autoimmune encephalitis 
between 2000 and 2014.  All but one patient had epileptic seizures as part of the clinical 
presentation. 16 patients were treated for status epilepticus at the time for disease onset, most of the 
time partial, and one for epilepsia partialis continua (EEG-verified). A majority of the patients had 
also cognitive problems and several had psychiatric disturbances. Hypoventilation and 
hyponatremia were encountered in single individuals. CSF samples from all three timepoints, onset, 
3±1 and 12±3 months (LP1, LP2 and LP3 respectively) were available from 12 patients; 8 patients 
performed LP just twice and 5 patients just once. At the time for disease onset, 20 patients were 
positive for CSF immunopathy and 5 negative. In 12 (48%) patients single or multiple antibodies 
(against neuronal surface, paraneoplastic or others) were found (2 Ma2, 3 GAD, 2 NMDA, 1 
voltage gated kalium chanel (VGKC) later characterized as LGI1, 1 TPO, 1 TPO+GAD, 1 
TPO+NMDA, 1 NMDA+GAD+TPO). In 13 patients, no antibodies were found. One of these 
patients had had a herpes 1 virus infection preceding with a few weeks the autoimmune 
encephalitis, but no signs of reactivation. It has been suggested previously that herpes encephalitis 
may trigger autoimmune processes (15). Three patients were treated before 2008 when the full 
antibody test battery was implemented. Malignancies were found in two patients (one mammary 
cancer and one neuroendocrine tumor). All but one patient were treated with at least one 
immunosuppressor. 
 
CSF neuronal damage and glial cells markers 
Results are shown in table 3.  
 
NFL levels at LP2 were significantly higher than levels at LP3. T-tau levels at LP1 were 
significantly higher than levels at LP3. GFAP levels did not differ significantly between the three 
LPs. NFL, T-tau and GFAP levels were correlated to age and to each other at LP1 and 2 but not at 
LP3.  
 
Increased CSF NFL, T-tau and GFAP levels at any time were present in 21, 19 and 14 out of 25 
patients, respectively. Three patients had normal levels of all brain damage markers. In one patient 
only CSF T-tau was increased. These four patients, all females, underwent LP just once.  Their 
outcomes at one year were good (mRS 1 and 2). Three of them had never had status epilepticus and 
one had had that but not at the time for LP. Their results were mixed in regard to CSF immunopathy 
and MR findings. Six patients (five females and one male) had at least one NFL value > 10000 ng/l. 
One of these had a good outcome at one year (mRS 1); the five others had bad outcomes (mRS 3-6), 
including patient 3 who was dead at one year. 
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CSF immunopathy: At LP3, out of 12 available CSF results, 4 still showed immunopathy. Of 
these, 2 showed still high NFL levels, one high GFAP, but T-tau was normal in all.   
 
Antibodies: Eight of the 12 patients who were positive for neuronal surface and/or other antibodies 
had high and four had normal levels of neuronal damage and glial cells markers. However, in these 
patients only LP1 was performed.  
 
MRI: At LP1, 15 patients had MRI abnormalities consistent with autoimmune encephalitis and 10 
had normal MRIs. Seven of these had high CSF NFL and five had high T-tau. At LP3, 10 patients 
had no brain MRI abnormalities. None of these had increased levels of T-tau protein and GFAP but 
four had still elevated NFL levels. In 10 patients, the MRI abnormalities diminished but were not 
entirely gone at LP3 and could have been permanent rests after the disease process. In six of these 
cases, T-tau protein had normalized, in one case it remained high. CSF NFL and GFAP remained 
high in five cases.  
 
Outcomes: At onset, 21 patients were severely disabled (mRS 3-6) and four were doing rather well 
(mRS 1-2). At three months, one patient deteriorated, 20 improved and two were unchanged. Data 
was missing for two of them. Outcomes at 12±3 months (LP3) varied from good (mRS 1-2) in 16 
patients, to bad in seven patients (mRS 3-6). For two patients there was no outcome data at one 
year.  
 
Correlations between parameters 
Spearman's correlation showed that CSF NFL levels were correlated with outcomes at LP1, 2 and 3 
respectively. T-tau levels were correlated with outcomes at LP1, and GFAP levels at LP1 and 2. 
However, there was no association between outcomes and NFL, T-tau and GFAP levels, when 
correcting for age. 
Levels of CSF NFL, T-tau and GFAP were correlated with status epilepticus at LP1 but the 
significance disappeared with age correction. 
There was no correlation between NFL, T-tau and GFAP levels, and the presence of CSF 
immunopathy, antibodies to neuronal surface or intracellular antigens, or positive findings on MRI 
at LP1 and LP3. CSF immunopathy, antibodies and MRI findings were not correlated either at LP1 
or at LP3.  
 
Discussion 
 
In this study we explored the pattern of CSF levels of two neuronal damage markers (NFL and T-
tau protein) and a glial cell marker (GFAP) in patients with autoimmune encephalitis, over one year 
from disease onset. We also looked for associations between the levels of these markers and 
outcomes, the presence of CSF immunopathy, neuronal antibodies and MRI findings.  
 
With some exceptions, CSF NFL was high at the time for disease onset but decreased and was in a 
third of cases normalized about one year later. At 3 months, levels were overall high and 
significantly increased compared with LP3, but, compared with onset, they could be both higher 
and lower. This pattern suggests that there may be a delay between the onset of symptoms and 
changes in CSF NFL.  
 
CSF T-tau levels were significantly higher at LP1 compared with LP3. At the time for LP2, CSF T-
tau levels had decreased and were sometimes normalized, in contrast to NFL, and at LP3 all but one 
of the available T-tau levels were normal. This restricted data seems to indicate that CSF T-tau 
reacts in the same fashion but faster than CSF NFL which seems to have a more protracted time 
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course.   
 
CSF GFAP seems to follow the same pattern as the neuronal markers, with high levels at onset and 
lower and normalized later on, but the differences over time were not statistically significant. These 
findings may indicate that the immunological process in autoimmune encephalitis is directed more 
specifically at neurons and not indiscriminately at the surrounding tissue including glial cells, as 
GFAP is a protein expressed mainly in fibrillary astrocytes.  
 
In neurodegenerative diseases, high CSF NFL levels are associated with disease severity and short 
survival (17) and in Creutzfeldt-Jakob's disease, the increase of T-tau levels is more pronounced in 
more advanced disease (18). In this study, no certain relationship could be established between NFL 
and T-tau levels, and disease severity, measured as outcomes at three timepoints over one year, but 
there seems to be a trend for a direct association. The two patients (no. 3 and 4) with the highest 
CSF NFL levels at LP1 and LP2 were also the least responsive to treatment and, at one year, the 
most disabled (mRS 4 and 6). Patient no. 3 was the only one who died at one year and autopsy 
confirmed the diagnosis showing rests after encephalitis. Three other patients with early five digits 
CSF NFL (no. 8, 16, 18) had at one year relatively high mRS scores (3), but one (no. 5) recovered 
almost completely (mRS 1). At one year, 2 of the 3 patients with the highest initial T-tau (>4000 
ng/l) showed a poor outcome (no. 3 and 16, mRS 3 and 5 respectively) but one had a good recovery 
(no. 5, mRS 1).  
 
CSF NFL and T-tau are known to be increased in several of the most important mimics of 
autoimmune encephalitis, such as Creutzfeldt-Jakob's disease, acute disseminated encephalo-
myelitis (ADEM), and brain infections (21, 22).  Thus, although increased CSF-NFL and total T-tau 
protein levels are not useful in the differential diagnosis of autoimmune encephalitis, they seem to 
be sensitive markers of ongoing disease activity with axonal and neuronal injury. 
 
There was no correlation between positive findings on brain MRI and increased levels of neuronal 
damage markers. These markers may be more sensitive for detecting disease activity as they were 
increased while the initial MRI in several patients was normal. In addition, neuronal damage and 
glial cell markers seem in several cases to normalize first, before brain MRI normalizes. The same 
argumentation seems to apply in regard to CSF immunopathy also. There is insufficient data in this 
study to conclude whether neuronal damage and glial cell markers are helpful in a still symptomatic 
patient when having to decide if symptoms and persistent abnormalities on brain MRI or CSF 
immunopathy indicate continued active disease or represent just sequels after a now suppressed 
disease processes. The available results may suggest that normalized CSF T-tau protein and NFL 
indicate an arrested disease process, that T-tau protein may react faster than NFL thus being more 
sensitive, and that both are better in this respect than brain MRI and CSF immunopathy, but the data 
is too limited to draw these conclusions.  
 
An important question which this study cannot definitely answer is whether the high levels of 
neuronal damage and glial cell markers are a result of the primary pathological mechanisms 
responsible for the autoimmune encephalitis, or merely a reflection of diffuse neuronal damage 
caused by status epilepticus. Supporting the first alternative is the fact that, although a majority of 
our patients had status epilepticus, there were a few with high NFL and T-tau levels without 
concomitant status epilepticus. In addition, we know of several unpublished cases of patients with 
status epilepticus as exacerbation of severe but not inflammatory or autoimmune chronic epilepsy 
who do not show any abnormalities in regard to CSF neuronal damage markers.  
The same considerations could also be raised regarding the cause of the MRI abnormalities which a 
large proportion of but not all patients with autoimmune encephalitis show: were they caused by the 
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inflammatory autoimmune processes or by status epilepticus? In this respect, it is generally assumed 
that MRI abnormalities are seen in a substantial proportion of patients with autoimmune 
encephalitis (8).  
 
This study does not inform on whether there is any relationship between levels of neuronal brain 
markers and the presence or the levels of neuronal surface and/or other antibodies in limbic 
encephalitis. Patients both positive and negative for antibodies have shown increased levels of 
neuronal damage and glial cell markers.  
 
The presence of specific antibodies directed against neuronal cell membranes or intracellular 
antigens is to a certain degree useful in the practical management of autoimmune encephalitis. 
Thus, assuming a credible clinical presentation, positive titers of antibodies directed at NMDA-
receptors make a diagnosis of NMDA-receptor encephalitis highly plausible, offer a consistent 
model for the disease processes, trigger prompt investigations for teratomas, and are expected to 
correlate to some degree with disease outcomes and relapses (7). However, their mere presence 
does not necessarily imply active disease as NMDA receptor antibodies can also be present in 
healthy individuals (23), in patients who have recovered from encephalitis (7) and also in 
Creutzfeldt-Jakob's disease (24). The same applies to other antibodies, as recent studies have found 
serosprevalence of several brain directed antibodies such as NMDAR1, amphiphysin, CASPR2, 
Ma1 and 2, GAD 65, in healthy and neuropsychiatrically ill subjects (25). Being entirely non-
specific, CSF neuronal damage and glial cell markers cannot be interpreted in the same way as the 
specific neuronal antibodies. They have no diagnostic value outside a specific clinical context and 
do not contribute with any etiological guidance. Nevertheless, their high sensitivity for indicating 
brain damage can be regarded as an asset in the context of autoimmune encephalitis, especially in 
those not very infrequent cases (52% of all patients, in this study) in which no specific antibodies 
can be detected, or in the treated but still symptomatic patient. In those cases, levels of neuronal 
damage and glial cell markers may be to some degree a substitute for, or a complement to titers of 
specific antibodies, and may offer support in the clinical management by informing on disease 
activity.  However, more studies are needed before this can be established. Future work regarding 
the usefulness of these markers in autoimmune encephalitis should probably not primarily focus on 
differential diagnosis aspects but rather on assessing disease activity. 
 
The available data from this study cannot be used to investigate whether there is a correlation 
between immunosuppression and the levels of neuronal damage and glial cell markers. All but one 
patient received at least one immunosuppressor during the disease course. Generally, treatment 
intensity was escalated according to the clinical situation, with more aggressive immunosuppression 
given to more treatment unresponsive, disabled patients. 
 
There are limitations to this study. First, the amount of data is restricted due to a low number of 
patients. Second, the available data is incomplete as three consecutive CSF samples and outcome 
measures at LP3 were not available from all patients. In addition, there is a risk for bias in this 
respect, as patients doing well were generally less prone to undergo repeated LP-s. Third, some 
patients with autoimmune encephalitis may have been missed by the selection process especially in 
the first years of this century as awareness regarding autoimmune encephalitides has markedly 
increased during the last 10 years. For several years, our clinic had a program for managing acute 
limbic encephalitis, and not autoimmune encephalitis in general, and this may have influenced the 
selection process to a certain degree in favor of patients with symptoms of limbic encephalitis. 
Fourth, the management of autoimmune encephalitis has changed during the period covered by this 
study, which makes more difficult a direct comparison of all patients. There may be differences 
between how patients were investigated and treated during the first half of the study period 
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compared with the second half, considering the evolution of the neurological community's 
understanding of these disorders. Fifth, there is a risk of bias in the selection of patients for this 
study, as all patients, at onset, were severely disabled and were hospitalized. Although 
hospitalization was an inclusion criterion, we are not aware of any out-patients with a suspected 
diagnosis of autoimmune encephalitis who did not pass through the neurological ward. Sixth, the 
inability of this study to show a significant association between the neuronal damage markers and 
outcomes may also be due to the heterogeneity of the time for disease onset. This time marked only 
the point in time when symptoms were severe enough for the patient to be hospitalized, and not the 
real time when the disease process started. Analysis of case histories showed that some patients 
developed epilepsy or other more dramatic symptoms from the beginning, which prompted them to 
seek medical care very early, while others had more subtle symptoms and come later to medical 
attention. Finally, retrospective retrieval of patient data always lowers its quality.  
 
In conclusion, CSF NFL and T-tau levels seem to reflect the disease course in autoimmune 
encephalitis with high early levels which decrease and sometimes normalize one year after disease 
onset, in parallel with amelioration of symptoms. This restricted data cannot confirm an association 
between the levels of these markers and disease severity but it suggests a trend for higher levels in 
more severe disease. Due to its limitation, particularly in respect with data quantity and quality, the 
findings of this study need replication by larger and longer studies. 
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Table 1 Demographics and clinical data. Modified Rankin Scale (mRS) score at onset (LP1), at 3±1 
month  (LP 2) and at 12±3 months (LP3) (unless stated otherwise).  
 
Patient Sex Age  Symptoms Status 
epilepticus 
(at onset)* 
Immuno-
suppressants 
mRS at 
LP1 
(onset) 
mRS at 
LP2 
mRS at 12±3 
months 
1 M 75 Ep, Cog Yes I 
5 3 
4 
(hydrocephalus) 
2 F 74 Ep, Cog Yes C 5 2 2 
3 F 68 Cog, hVent, 
Diz 
No C P 
3 4 6 
4 F 68 Ep, Cog Yes C 5 5 5 
5 M 69 Ep, Cog, 
hNa 
Yes C 
5 2 1 
6 F 66 Ep, Cog Yes C 5 3 3 
7 M 46 Ep Yes None 5 2 2 
8 F 55 Ep, Cog Yes C 5 3 3 
9 M 48 Ep, Cog Yes C 5 2 2 
10 M 43 Ep, Cog, Psy Yes C I P 5 3 3 
11 M 45 Ep, Cog Yes C A 5 3 2 
12 F 42 Ep Yes C I P M R 5 2 2 
13 F 39 Ep, Cog, Psy No C I P A 1 1 1 
14 F 37 Ep, Psy Yes C I  5 3 2 
15 F 36 Ep, Psy Yes I 5 - 2 
16 F 29 Ep, Cog, Psy Yes C P 5 3 3 
17 F 31 Ep, Psy No C 2 1 1 
18 F 31 Ep, Psy Yes C I P 5 4 3 
19 F 28 Ep, Cog, Psy Yes C Cy 5 3 2 
20 F 25 Ep, Cog, Psy No C I P 3 2 2 
21 M 27 Ep, Cog, Psy No C P 5 4 2 
22 M 19 Ep, Cog No C 3 1 1 
23 F 20 Ep, Cog, Psy Yes C I P R 5 1 1 
24 F 18 Ep, Cog, Psy No C 2 1 1 
25 F 43 Ep, Cog No Cc 1 - - 
 
Symptoms 
C = Cognition 
Diz = Dizziness 
Ep = Epilepsy (including status epilepticus, epileptic seizures) 
hNa = Hyponatremia 
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hVent = Hypoventilation 
Psy = Psychiatric symptoms 
 
Immunosuppressants 
A = Azathioprin 
C=Intravenous corticosteroid pulse 
c = Peroral corticosteroid cure 
I = Intravenous high dose immunoglobuline 
M = Mycophenolat mofetil 
P = Plasmapheresis 
R = Rituximab 
 
LP = lumbar puncture; mRS = modified Rankin Scale score 
 
* Unless stated otherwise 
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Table 2 CSF immunopathy and MRI findings at onset (LP1) and at 12±3 months (LP3) (unless 
stated otherwise). Antibodies and results of malignancy workup. 
 
Patient CSF LP1 
immuno-
pathy 
CSF LP3 
immuno-
pathy 
MRI LP1 
findings 
MRI LP3 
findings 
Antibody Malignancy 
1 Yes Yes Yes Rests Neg Neg 
2 No - Yes - Neg Mammar 
3 Yes - Yes Rests Neg Neg 
4 Yes - Yes Progress Neg (post herpes) Neg 
5 Yes No Yes Rests Ma2 Neg 
6 Yes Yes Yes Rests NMDAR, GAD,  
TPO 
Neuro-
endocrine 
7 Yes - No No Neg Neg 
8 Yes No Yes Rests Neg Neg 
9 No - Yes No (at 
LP2) 
Neg Neg 
10 No No Yes Rests Neg Neg 
11 Yes Yes Yes No GAD Neg 
12 Yes - No - VGKC (LGI1) Neg 
13 No - Yes Rests Ma2 Neg 
14 Yes No No No NMDAR Neg 
15 Yes - Yes Rests Neg Neg 
16 Yes No No No Neg Neg 
17 Yes - Yes Rests GAD Neg 
18 No No Yes Rests Neg Neg 
19 Yes No No No TPO Neg 
20 Yes Yes Yes Yes TPO, GAD Neg 
21 Yes - No No NMDAR, TPO Neg 
22 Yes No No No Neg Neg 
23 Yes - No No NMDAR Neg 
24 Yes - No No Neg Neg 
25 Yes - No - GAD Neg 
Antibodies: GAD = glutamic acid decarboxylase; NMDAR = anti-N-methyl-D-aspartate receptor; 
TPO = thyroid peroxidase; VGKC = voltage gated kalium chanel. 
CSF = cerebrospinal fluid; LP = lumbar puncture 
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Table 3 CSF levels of neuronal damage markers at onset (LP1), 3±1 months (LP2) and 12±3 
months (LP3). Levels marked with * are normal (for age), all the others are increased. 
 
Patient NFL 1 NFL 2 NFL 3 T-tau 
1 
T-tau 
2 
T-tau 
3 
GFAP 
1 
GFAP 
2 
GFAP 
3 
1 4469 - 2719 1230 - 290* 960* - 2910 
2 4063 - - 2520 - - 1400 - - 
3 54063 179688 - - 5330 - - 1480 - 
4 32500 32600 - 2850 1950 - 1810 350* - 
5 5560 12200 870* 6910 500 353* 520* 560* 360* 
6 6000 4240 1700* 434 168* 157* 1650 1430 1060* 
7 5313 6031 - 520 310* - 320* 530* - 
8 9530 44700 2760 2000 2930 328* 1300 930 430 
9 3580 7920 - 3090 233* - 600* 420* - 
10 < 781* 9094 3438 1120 1190 240* 570 620 280 
11 1310 1330 480* 541 138* 155* 380* 340* 180* 
12 - 410* - - 137* - - 290* - 
13 < 781* - - 140* - - 90* - - 
14 High 960 720 - 100* 110* - 580* 320* 
15 2700 1520 940 420 250* 168* 7810 930 2560 
16 2531  31875 5906 4290 640 240* 940* 520* 590* 
17 1094*  - - 360 - - 180* - - 
18 2550 19300 1220 1400 1230 408 250* 650 360 
19 3510 1710 340* 840 200* 200* 280* 400* 420* 
20 250 - 490 150* - 108* 220* - 110* 
21 740 1800 - 211* 114* - 50* 420 - 
22 400  480 300* 635 243* 160* 460 400 330* 
23 4810 4440 High 1130 227* - 270* 310* - 
24 210* 390 - 295 136* - 230 190 - 
25 310* - - 
 
188* - - 400* - - 
CSF = cerebrospinal fluid; GFAP = glial fibrillary acidic protein; LP = lumbar puncture; NFL = 
neurofilament light chain; T-tau = total tau protein. 
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